The effect of adipose cell size on the measurement of GLUT 4 in white adipose tissue of obese mice

Glucose transporter (GLUT 4) was assessed in subcellular membrane fractions of white adipose tissue (WAT) from obese insulin-resistant aurothioglucose (AuTG)- or monosodium glutamate (MSG)-treated mice. Obesitywas demonstrable by increased body weight and/ or Lee index, as well as by the heavier WAT and brown adipose tissue in relation to similar weights of gastrocnemius and heart. In vivo insulin-resistance in obese animals was suggested by moderate hyperglycemia and severe hyperinsulinemia. Morphological analyses of adipose cells showed a > 10-fold increase in cell volume of obese mice. Subcellular fractionation indicated a reduced (P<0.01) protein membrane content in the fat-free extract (FFE) from obese mice. However, the specific activity of 5'nucleotidase, a plasma membrane (PM) marker, in EFE and PM did not differ among groups. In addition, the total PM enzyme activity per unit of cell surface area was also unchanged. The GLUT 4 content, assessed by Western blotting and expressed per µg membrane protein, was reduced by ~50 percent (P<0.01) in all membrane fractions from obese animals. However, the total FFE GLUT 4 content per cell was increased...

Terapêutica coadjuvante no tratamento do pênfigo foliáceo sul-americano com auranofina: estudo duplo-cego / Coadjuvant therapy with auranofin in the treatment of the South American pemphigus foliaceus: a double blind study

Os autores descrevem suas experiência do uso de auranofina como tratamento coadjuvante na terapêutica do pênfigo foliáceo sul-americano em estudo duplo-cego e chamam a atençäo para os efeitos produzidos pela auranofina nos parâmetros imunológicos da doença. Afirmam que a droga tem sua utilidade no tratamento de pacientes portadores de pênfigo, no entanto sugerem o prosseguimento da pesquisa

Valoracion clinica - eficacia y tolerancia - de un nuevo compuesto quimico (auranofin) por via oral en el tratamiento de la artritis reumatoide. / Clinical evaluation-efficacy and tolerance - of a new chemical compound (auranofin) by oral administration in the treatment of rheumatoid arthritis

El presente estudio resume la experiencia obtenida con el empleo de crisoterapia oral - auranofin - en 22 pacientes afectados por artritis reumatoide. El tratamiento vario entre 6 y 36 meses.Se administraron 6 mg de auranofin diariamente, en una sola toma o repartida en dos. Los resultados fueron alentadores: 17 enfermos terminaron el estudio, en 4 hubo remision, en otros 4 resultados catalogados como muy buenos, buenos en 4 mas, ligeros en 3 y malos o desfavorables en 2. Se suspendio el tratamiento en 4 enfermos; 3 de ellos por efectos indeseables (1 neutropenia, 1 sensibilidad al oro, 1 agravacion de la AR) en el cuarto caso por embarazo. Hubo una desercion